Results 51 to 60 of about 28,236 (118)

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]

Pharmacoepidemiol Drug Saf
Aloke C, Adelusi OA, Onisuru OO, Iwuchukwu EA, Achilonu I.   +4 more
europepmc   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Liver Cirrhosis: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Shetty USA, Batool AE, Postoev A, Mohammed Abdul RH, Chaudhary S, Jabeen S, Wei CR, Amin A.   +7 more
europepmc   +1 more source

Analysing the Shift in Prescribing Patterns: Sodium Glucose Co-transporter 2 Inhibitors, Dipeptidyl Peptidase 4 Inhibitors and Traditional Antidiabetic Drugs

Online Journal of Health & Allied Sciences
India currently has around 77 million adults living with diabetes. Considering the growing impact of diabetes-related complications, we aimed to compare the real-world prescribing patterns of sodium-glucose cotransporter-2 inhibitors, dipeptidyl ...
Vini Pavithran, Pandiyan Balachandran, Chadappully Ismail Sajeeth, Athiappan Hariharan   +3 more
doaj  

Caution in handling switchers in pharmacoepidemiologic studies estimating treatment effects: the example of dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease. [PDF]

Am J Epidemiol
Wang T, Wang J, Song Z, Miller E, Pate V, Her Q, Yang J, Charlier SHR, Egger P, Barnes EL, Buse JB, Becker C, Sandler RS, Meier C, Jick S, Stürmer T.   +15 more
europepmc   +1 more source

Phenotype-Specific Mortality Outcomes with Dipeptidyl Peptidase-4 Inhibitors in Heart Failure and Diabetes: Real-World Evidence from a Retrospective Single-Center Cohort Study. [PDF]

J Clin Med
Alfehaid L, Alamer A, Alhantush A, Yami MSA.   +3 more
europepmc   +1 more source

Cardiovascular and renal outcomes of sodium-glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients. [PDF]

Diabetol Metab Syndr
Badran AS, Gbreel MI, Tawfik AM, Balata M.   +3 more
europepmc   +1 more source

DPPPRED-IV: An Ensembled QSAR-Based Web Server for the Prediction of Dipeptidyl Peptidase 4 Inhibitors. [PDF]

Int J Mol Sci
Carpio LE, Olivares M, Ortega-Vallbona R, Serrano-Candelas E, Sanz Y, Gozalbes R.   +5 more
europepmc   +1 more source

Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis. [PDF]

Curr Ther Res Clin Exp
Tuersun A, Cui S, Han L, Aikebaier A, Shi Y, Cheng G, Cheng L, Ma G.   +7 more
europepmc   +1 more source

Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection. [PDF]

Int J Ophthalmol
Chung YR, Kim C, Lee E, Lee K.
europepmc   +1 more source

Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes. [PDF]

J Intern Med
Hung TY, Lin TC, Liou YJ, Lin TH, Hsu YJ, Lin LY, Wang MT.   +6 more
europepmc   +1 more source